Brian Park, PharmD

Drug Information Specialist https://www.clinicaladvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Infectious Diseases Information Center

Flucelvax Quadrivalent Approval Expanded to Include Younger Patients

Brian Park, PharmD

October 20, 2021

The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.

Cardiovascular Disease Information Center

USPSTF: Starting Aspirin in Patients 60 or Older for Primary CVD Prevention Not Recommended

Brian Park, PharmD

October 14, 2021

Starting aspirin in patients 60 years or older to prevent a first heart attack or stroke is not recommended.

Infectious Diseases Information Center

Emergency Use Request Submitted for Molnupiravir for Mild to Moderate COVID-19

Brian Park, PharmD

October 14, 2021

The submission is based on data from the phase 3 MOVe-OUT trial, which evaluated molnupiravir in 775 nonhospitalized adults with mild to moderate COVID-19.

Gastroenterology Information Center

Risk of Chronic Otitis Media With Effusion Up in GERD Patients

Brian Park, PharmD

October 13, 2021

Researchers conducted a retrospective, propensity score-matched cohort study using data from the Korea National Health Insurance Service.

Infectious Diseases Information Center, News

Pfizer-BioNTech COVID-19 Vaccine Booster Dose Authorized for High-Risk Individuals

Brian Park, PharmD

September 24, 2021

A single booster dose may be administered to individuals 65 years and older and those at high risk of severe disease or exposure to SARS-CoV-2.

Infectious Diseases Information Center

Bamlanivimab Plus Etesevimab Authorized for COVID-19 Postexposure Prophylaxis

Brian Park, PharmD

September 22, 2021

Postexposure prophylaxis with bamlanivimab plus etesevimab is not a substitute for vaccination against COVID-19.

Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple d

Hospital Medicine Information Center

CDC: Delta-8 THC Products Linked to Increase in Adverse Events

Brian Park, PharmD

September 20, 2021

Delta-8 THC products have not been evaluated or approved by FDA for safe use in any context.

Pain Management Information Center

Trudhesa Nasal Spray Approved for Acute Treatment of Migraine

Brian Park, PharmD

September 20, 2021

The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.

Dermatology Information Center

Atopic Dermatitis Improvements Seen in Very Young Treated With Dupilumab

Brian Park, PharmD

September 8, 2021

The phase 3 trial evaluated dupilumab, in addition to standard of care low potency topical corticosteroids, in 162 patients aged 6 months to 5 years with uncontrolled moderate to severe atopic dermatitis.

Cardiovascular Disease Information Center

Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction

Brian Park, PharmD

September 2, 2021

The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.

Next post in Cardiovascular Disease Information Center